Advances in Nano Vaccines: Covid-19

dc.contributor.author Keskin, Cumali
dc.contributor.author Nasibova, A.
dc.contributor.author Baran, Mehmet Fırat
dc.contributor.author Selimoğlu, A.
dc.contributor.author Baran, M.F.
dc.contributor.author Keskin, C.
dc.contributor.other 21.02. Department of Medical Services and Techniques / Tıbbi Hizmetler ve Teknikleri Bölümü
dc.contributor.other 21. Vocational School of Health Services / Sağlık Hizmetleri Meslek Yüksekokulu
dc.contributor.other 01. Mardin Artuklu University / Mardin Artuklu Üniversitesi
dc.date.accessioned 2025-02-15T19:38:44Z
dc.date.available 2025-02-15T19:38:44Z
dc.date.issued 2023
dc.description.abstract Nanovaccines are considered a new approach in vaccination methodology specially for Covid-19 infection. Nanovaccines are more effective than conventional vaccines; Because ofhumoral and cellular immune responses which are simultaneously induced. Nano vaccines are assumed to upregulate the immune system as well as infection prevention. They are probably promising candidates for chronic autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, AIDS, and COVID-19 infectious. Based on this, we will describe the different working mechanisms of nanoparticles. In addition, applicable nano vaccines which have been approved for COVID-19 therapy Covid 19 are described. Antigen-carrying nanoparticles can affect the immune response and significantly enhance cell-T cytotoxic response. Nanoscale particles can improve vaccine efficiency because of their biomedical benefits. These properties include Small size, which allows better penetration into tumors and more half-life tumor cells. Current vaccines, however, are required to re-formulate almost because of gradual antigen modifications. More ever these vaccines do not protect against mutations and the low half-life of current vaccines due to limitations of current technologies. Nano vaccine formulation improvements have been required to induce a widespread and potent immune response. In this review, we provide an overview ofthe types and applications of nanoparticles in vaccines and their outstanding properties that made them alternatives for Covid-19 treatment. © 2023, Bentham Books imprint. en_US
dc.identifier.citationcount 0
dc.identifier.doi 10.2174/9789815079692123010011
dc.identifier.isbn 9789815079692
dc.identifier.isbn 9789815079708
dc.identifier.scopus 2-s2.0-85208867348
dc.identifier.uri https://doi.org/10.2174/9789815079692123010011
dc.identifier.uri https://hdl.handle.net/20.500.12514/6258
dc.language.iso en en_US
dc.publisher Bentham Science Publishers en_US
dc.relation.ispartof Nanopharmacology and Nanotoxicology: Clinical Implications and Methods en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Covid-19 en_US
dc.subject Inorganic Nanoparticle en_US
dc.subject Nano Vaccines en_US
dc.subject Virus-Like Particles en_US
dc.title Advances in Nano Vaccines: Covid-19 en_US
dc.type Book Part en_US
dspace.entity.type Publication
gdc.author.scopusid 54400817900
gdc.author.scopusid 41961222100
gdc.author.scopusid 57222658389
gdc.author.scopusid 59408222100
gdc.author.scopusid 57225396789
gdc.author.scopusid 57819807000
gdc.description.department Artuklu University en_US
gdc.description.departmenttemp Asefy Z., Maragheh University of Medical Sciences, Maragheh, Iran; Nasibova A., Biophysics and biochemistry department, Baku State University, Baku, Azerbaijan, Institute of Radiation Problems, Azerbaijan NationalAcademy of Science, Baku, Azerbaijan; Hoseinnejhad S., Maragheh University of Medical Sciences, Maragheh, Iran; Selimoğlu A., Department of Otolaryngology, Hacettepe, University Faculty of Medicine, Sihhiye, Ankara, Turkey; Baran M.F., Department of Food Technology, Vocational School of Technical Sciences, Batman University, Batman, Turkey; Keskin C., Department of Biology, Mardin Artuklu University Graduate Education Institute, Mardin, 47200, Turkey en_US
gdc.description.endpage 206 en_US
gdc.description.publicationcategory Kitap Bölümü - Uluslararası en_US
gdc.description.scopusquality N/A
gdc.description.startpage 195 en_US
gdc.description.wosquality N/A
gdc.scopus.citedcount 0
relation.isAuthorOfPublication 372246d5-4a94-4c92-b9e4-3b9bbbbb9d54
relation.isAuthorOfPublication 46dcad93-7820-41cd-a3f0-d9c947668113
relation.isAuthorOfPublication.latestForDiscovery 372246d5-4a94-4c92-b9e4-3b9bbbbb9d54
relation.isOrgUnitOfPublication 256d1c0a-4c75-476b-b468-80c6b6a899f2
relation.isOrgUnitOfPublication 98e86623-06a0-4127-be83-a120e4f62572
relation.isOrgUnitOfPublication 39ccb12e-5b2b-4b51-b989-14849cf90cae
relation.isOrgUnitOfPublication.latestForDiscovery 256d1c0a-4c75-476b-b468-80c6b6a899f2

Files